SUBSCRIBE
SUBSCRIBE

GSK Bio

NEWS
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Business
Scandal-Hit GlaxoSmithKline to Chop 1,000 Staffers in China
January 22, 2015
 · 
2 min read
BioSpace's List of Five Companies Who Will Have a New Year, New You in 2015
Biotech Bay
BioSpace’s List of Five Companies to Watch in 2015: Aegerion, AbbVie, Tekmira, Novartis AG, GlaxoSmithKline
January 21, 2015
 · 
12 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Top CROs Like Quintiles, Inc. Stay Mum About Rumored Pfizer Deal
January 20, 2015
 · 
2 min read
Job Trends
270 Jobs Chopped as Novartis AG to Shutter Plant and Outsource to Eli Lilly
January 19, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
With Some Help, GlaxoSmithKline Believes They Have Found Cancer’s “Achilles Heel”
January 14, 2015
 · 
2 min read
Job Trends
PAREXEL International to Hire 450 Ex-GlaxoSmithKline Employees
January 7, 2015
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Business
Isis Pharmaceuticals, Inc. Rockets as Johnson & Johnson Snags Bowel Drug License Option for $835 Million
January 5, 2015
 · 
2 min read
GlaxoSmithKline In A Crises Or Just Routine Restructuring?
December 31, 2014
 · 
1 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
NewLink Genetics, Merck & Co. Nabs $30 Million Government Contract For Ebola
December 22, 2014
 · 
2 min read
Load More
  • 2026 - Best Places to Work - Badge (1).png
JOBS
IN THE PRESS
Press Releases
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
 · 
9 min read
Press Releases
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
November 12, 2024
 · 
4 min read
Press Releases
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
November 5, 2024
 · 
7 min read
Press Releases
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 8, 2024
 · 
10 min read
Pharm Country
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 7, 2024
 · 
5 min read
Pharm Country
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
 · 
6 min read
Deals
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
 · 
7 min read
Business
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 2, 2022
 · 
5 min read